Kocitaf 50mg/200mg/25mg Tablet is unsafe to implement in people with liver disorder and should be prevented.This innovative drug is generally getting explored for its possible part in oncology, particularly targeting several kinds of cancer. Scientists are also investigating its software in autoimmune disorders, aiming to leverage its unique system